Neutrogena Rapid Clear Treatment Pads

Description

NEUTROGENA Rapid Clear Treatment Pads are formulated with salicylic acid, a recognized acne treatment agent, and incorporate MICROCLEAR™ technology to enhance efficacy. Each container includes 60 pads, each measuring 2.12 inches (5.50 cm) in diameter. These pads are designed to deep clean dirt and oil from the skin, resulting in a clean and smooth complexion.

Uses and Indications

This drug is indicated for the treatment of acne.

There are no teratogenic effects associated with this medication. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

Healthcare professionals are advised to cleanse the skin thoroughly prior to the application of this product. The affected area should be covered with a thin layer of the product one to three times daily.

To minimize the risk of excessive drying of the skin, it is recommended to initiate treatment with one application per day. Based on the patient's response and as directed by a physician, the frequency may be gradually increased to two or three times daily.

In cases where bothersome dryness or peeling occurs, the application frequency should be reduced to once daily or every other day to alleviate these symptoms.

Contraindications

Use is contraindicated in the following situations:

• The product should be kept out of reach of children to prevent accidental ingestion. If swallowed, immediate medical assistance or contact with a Poison Control Center is required.

• In cases of skin irritation, it is advised to use only one topical acne medication at a time to avoid exacerbating the condition.

Warnings and Precautions

For external use only. This product is flammable; therefore, it must be kept away from fire or flame to prevent any risk of ignition.

It is imperative to keep this product out of the reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

Side Effects

Patients using this product should be aware that it is intended for external use only. The formulation is flammable; therefore, it is essential to keep it away from fire or flame to prevent any hazardous situations.

Common adverse reactions include skin irritation and dryness, which are more likely to occur if patients use another topical acne medication concurrently. In the event of skin irritation, it is advised that only one topical acne medication be used at a time to minimize the risk of adverse effects.

In cases of accidental eye contact, patients should flush the affected area thoroughly with water to alleviate any discomfort.

Additionally, if the product is ingested, it is crucial to seek medical assistance or contact a Poison Control Center immediately to ensure proper care and management.

Drug Interactions

Concurrent use of topical acne medications may increase the risk of skin irritation and dryness. It is advisable to limit the use of topical acne treatments to one at a time to minimize the potential for adverse effects. If irritation occurs, the patient should discontinue the use of additional topical acne medications and consult a healthcare professional for further guidance.

Packaging & NDC

Below are the non-prescription pack sizes of Neutrogena Rapid Clear Treatment Pads (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely to ensure the medication is kept out of reach, as ingestion may require immediate medical attention or contact with a Poison Control Center.

For topical application, it is recommended to initiate treatment with one application daily to minimize the risk of excessive skin drying. Dosage may be gradually increased to two or three times daily based on clinical need or physician guidance. Should patients experience bothersome dryness or peeling, the frequency of application should be reduced to once daily or every other day.

Geriatric Use

Elderly patients may not have specific information regarding the use of Neutrogena Rapid Clear Treatment Pads, as the drug insert does not provide details on dosage adjustments, safety concerns, or special precautions for this population. Therefore, healthcare providers should exercise caution when considering the use of this product in geriatric patients, as individual responses may vary. Monitoring for efficacy and potential adverse effects is advisable in this demographic, given the absence of targeted data.

Pregnancy

Safety during pregnancy has not been established for this product. The use of this product is not recommended during pregnancy due to potential risks to the developing fetus. The effects of salicylic acid on fetal development are not well studied; therefore, caution is advised. Women who are pregnant or planning to become pregnant should avoid using this product. It is recommended that healthcare providers be consulted for advice on use during pregnancy, including any necessary dosage modifications.

Lactation

There are no specific warnings or considerations regarding nursing mothers or lactation mentioned in the provided text. Therefore, healthcare professionals may consider the use of this medication in lactating mothers without specific contraindications. Further monitoring of breastfed infants may be warranted, although no data on excretion in breast milk or effects on nursing infants are provided.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise caution and consider the individual patient's liver status when prescribing this medication.

Overdosage

In the event of an overdosage, immediate medical assistance is crucial. If the substance is ingested, healthcare professionals should advise patients or caregivers to seek medical help or contact a Poison Control Center without delay.

Prompt intervention is essential to mitigate potential adverse effects associated with overdosage. Symptoms may vary depending on the specific substance involved; therefore, a thorough assessment by a medical professional is recommended to determine the appropriate course of action.

Management procedures may include supportive care and symptomatic treatment, tailored to the individual patient's needs. It is imperative that healthcare providers remain vigilant and prepared to address any complications that may arise from an overdosage scenario.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. In the event of swallowing the medication, patients should be instructed to seek medical help or contact a Poison Control Center immediately.

Patients should be made aware that using this medication in conjunction with other topical acne treatments may increase the likelihood of skin irritation and dryness. It is recommended that patients use only one topical acne medication at a time to minimize the risk of irritation.

Additionally, healthcare providers should inform patients about the importance of avoiding eye contact with the medication. In case of accidental eye contact, patients should be instructed to flush the eyes thoroughly with water to ensure safety and reduce potential harm.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature to maintain its efficacy and stability. No special handling requirements are noted, ensuring straightforward management within standard storage conditions.

Additional Clinical Information

The product is administered topically, with a recommended application of a thin layer covering the entire affected area one to three times daily. Clinicians should counsel patients regarding sun sensitivity, as the product contains an alpha hydroxy acid (AHA) that may increase the risk of sunburn. Patients are advised to use sunscreen, wear protective clothing, and limit sun exposure during treatment and for one week following discontinuation.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Neutrogena Rapid Clear Treatment Pads, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)